data collection are in place. Large RCTs of critical illnessnutrition interventions-such as glutamine therapy or early supplemental calorie provision-appear regularly in prestigious medical journals. 2 No doubt there are serious practical barriers to carrying out high-quality nutrition RCTs in critically ill patients. They include the heterogeneity of disease diagnoses, their severity, and their clinical trajectories; the need to identify specific subsets of critically ill patients who are most likely to benefit from a particular nutrition intervention; and the difficulty obtaining research funding for costly clinical trials of unprofitable generic therapies like nutrients. It is the premise of this article that these barriers can be overcome by physiologically literate clinical trial design. The title of this article is the one given to the conference presentation it is derived from. A more pertinent title would be, "Is it possible to investigate and identify protein requirements in specific ICU situations by adhering to physiologically rigorous nutrition principles?" The article explains 4 topics pertinent to this question. An important emphasis is placed on the need to design these clinical trials in ways that allow their conclusions to be implemented easily into routine clinical care.
High-Quality Clinical Trials Are Long Overdue
A relatively vast amount of consistent animal and human metabolic evidence, a small number of N balance studies that consistently indicate superior N balance when greater amounts of protein are provided, and observational data that deficient protein provision predicts worse clinical outcomes have long persuaded and continue to persuade clinical nutrition experts worldwide that catabolic critical illness increases protein requirements substantially above normal. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] The point can legitimately be made that more sophisticated metabolic and biomarker data regarding the interactions among critical illness and nutrition could better inform the design of the hard end-point trials that are necessary to improve clinical outcomes in the ICU. But the existing evidence is already vast. There is no controversy about it. What we don't know is this: how much protein should be provided to which patients, and how soon in the course of their critical illness? The only way to answer those questions is by carrying out pragmatic clinical trials. Yet the number of high-quality clinical studies carried out to answer these questions over more than 40 years is astoundingly small. (By comparison, more than 2 dozen RCTs have been carried out to test the benefits of 1 nonessential amino acid, glutamine, with disappointing results. 1 ) What factors should be considered when designing clinical trials that aim to identify a specific value for the protein requirement of individual, critically ill patients? No one doubts that different patients may have very different protein requirements. What clinical-metabolic signature identifies the patients whose protein requirement is most likely to be increased, and who are thus most appropriate to enroll in protein dose-identifying clinical trials? What outcome indicators should be used (a) to identify the patients whose protein requirement is most likely to be greatly increased; (b) as biomarkers in small, preliminary dose-finding trials; or (c) as hard clinical outcomes? What is the appropriate "dose" of protein and energy to prescribe critically ill patients in view of (a) the need to define an accurate, clinically practical body weight denominator and (b) the need to distinguish between the average requirement-the amount of nutrient that is adequate for only half of a population-and the "safe" requirement, which meets the needs of 97% of the population?
Catabolic Critical Illness Almost Certainly Increases Protein Requirements, but We Don't Know by How Much
Critical care nutrition care guidelines published in 2009 10 and 2016 11 were hindered in their recommendations about optimum protein provision by the almost total lack of reliable evidence on this topic. Indeed, the Canadian critical care nutrition guidelines, acknowledging this lack, declined to make any recommendation about the optimum level of protein provision. 14 A systematic review of the available evidence published in 2012 concluded that the recommendations regarding protein provision in previous reviews and guidelines were biased by incomplete enumerations of very low-quality studies that were burdened by serious flaws, including a lack of the statistical power necessary to identify any particular level of protein provision as superior, failure to clearly define critical illness, failure to identify the "denominator" (ie, grams of protein per kilogram of what?), failure to distinguish between average and safe levels of protein provision, failure to appreciate that parenteral amino acid mixtures contain less protein substrate than enterally delivered intact proteins, and the reliance, in most of them, on a metabolic marker-N balance-rather than on hard clinical outcomes. 3 There is plainly an urgent need to for highquality clinical studies to identify the minimum and safe amount of protein to provide critically ill patients. 13 How should they be designed?
Metabolic Features Pertinent to Individual Protein Requirements
Protein requirements vary widely among healthy individuals, and they doubtless vary even more widely in patients for whom the diagnosis of "critical illness" is often based simply on the fact that they are being treated in an ICU. What specific features should be used to identify patients whose protein requirement is most likely to be increased and the patients who are most likely to benefit from sufficiently generous protein provision? The physiological evidence suggests 3 obvious ones.
Increased Body Nitrogen Loss Indicates an Increased Protein Requirement
The metabolic feature that defines "catabolic" critical illness is a greatly increased rate of net muscle protein catabolism, with an associated increase in the rate of obligatory body N loss and inefficient dietary protein retention. The concept of a "minimum protein requirement" rests on the premise that individuals must consume an amount of protein at least equal to their rate of endogenous obligatory N loss (with an adjustment for the maximum efficiency of dietary protein retention). 1 It is physiologically rational to predict that patients who are experiencing greatly increased body N loss have an increased protein requirement. The only currently known, clinically practical way to identify states of increased obligatory N loss is by measuring the rate of body N loss. Total N is not commonly measured in hospital laboratories, but urinary urea N is easy to measure. Protein nutrition evaluations based on urinary urea N excretion have been successfully used for many decades to identify protein-catabolic patients. 4, 8, 15 As valuable as it is, urinary urea N excretion is a relatively imprecise indicator of body N loss. 1 Are simpler or more precise alternatives to urinary urea excretion (or N balance) available to identify protein-catabolic critically ill patients? Could indicators like body temperature or circulating biomarker concentrations provide equivalent information? This is a reasonable hypothesis, but any candidate indicator (or panel of indicators) will have to be validated against the gold standard of the measured rate of body N loss. For example, it is commonly presumed that standard critical illness severity scores effectively identify the most highly protein-catabolic patients, but data supporting this assumption are lacking. Indeed, the only published study that examined this relationship, in multiple-trauma patients, found no association between critical illness severity scores and rates of body N loss. 16 This observation should not be particularly surprising. Critical illness severity scores were developed and validated to predict death, not N loss. Scores that are designed to predict death from all causes may not reliably identify patients whose protein requirement is increased because critically ill patients die for many reasons. Sufficiently generous protein provision cannot be expected to reduce all death, only death that is hastened by a lack of sufficient dietary protein.
Muscle Atrophy
Catabolic critical illness triggers rapid and often debilitating muscle atrophy. 13, 17, 18 Although some patients have a normal muscle mass upon admission to an ICU, a significant proportion already has generalized muscle atrophy before their critical illness develops. 19 The causes of generalized muscle are many. They include preexisting protein-energy malnutrition, old age-related muscle atrophy (sarcopenia), disuse muscle atrophy, and high-dose glucocorticoid therapy. Unfortunately, even obvious muscle atrophy is commonly unidentified or disregarded in routine clinical practice, partly because of healthcare worker unawareness of its clinical implications and partly because the subcutaneous fat store of modern, critically ill patients is often adequate or excessive, creating the misleading impression that they are well nourished. 2 These 2 factors interact. Net muscle protein catabolism follows approximately first-order ("decay") kinetics, such that the rate of N loss from muscle is proportional to the existing total amount N available to be lost. 20 Highly protein-catabolic, muscle-atrophic patients will lose less body N/d in absolute terms than equally catabolic patients whose existing muscle mass is normal, but they are nonetheless at greater risk of succumbing to their critical illness. [21] [22] [23] First, the muscle-atrophic patient is closer to the cliff edge of lethal muscle depletion, and second, a patient whose muscle mass is depleted cannot release amino acids at a rate sufficient to meet the body's urgent need for protein synthesis at sites of injury and in the central protein pool to regulate the immuno-inflammatory process.
Bedside Evaluation of Muscle Mass
Protein and calorie doses are almost universally recommended per kilogram of body weight, because body weight is the most suitable surrogate for body cell mass. 1 But critical illness and its treatment create large shifts of extracellular fluid volume that render body weight an extremely unreliable surrogate for body cell mass. Growing appreciation of the importance of muscle mass determinations in disease has spurred efforts to develop body composition techniques and predictive equations suitable for bedside use. 24 Serum creatinine concentration and urinary creatinine excretion predict muscle mass. 23, 25 Bedside muscle imaging by ultrasound offers considerable promise. 26 Computerized tomography is a promising research technique. 21, 22 None of these determinations are currently carried out in routine ICU practice, but as clinical research continues to further confirm their relevance to clinical care, many could easily be incorporated into it.
A final, simple, but neglected way to evaluate a patient's muscle mass is bedside physical examination. Well-written articles and guidelines are available that explain bedside nutrition assessment, including the bedside evaluation of muscle mass. [27] [28] [29] It would be desirable to use sophisticated technology to validate simple bedside procedures for estimating any patient's muscle mass using the eyes and hands of the examining dietitian, nurse, or physician.
As we await the routine implementation of some of these approaches, practicing physicians will have to continue to use the imperfect denominator of body weight, appropriately adjusted for abnormal extracellular fluid volume and obesity. One simple method is to use patients' height to predict the body weight they would have if their body mass index (weight in kg/height in meters squared) was 23 or 24.
Negative Energy Balance Increases the Dietary Protein Requirement
Energy deficiency increases obligatory N loss and increases the dietary protein requirement. 1, 20, 30 The American Society for Parenteral and Enteral Nutrition (ASPEN) recommends that critically ill obese patients receive calories equal to approximately two-thirds of their estimated or measured energy expenditure with a compensatory increase of protein provision to either 2.0 or 2.5 g/kg of estimated nonobese dry body weight, depending on the severity of the obesity. 31 This physiologically sound recommendation is based on observational and metabolic evidence as well as some RCT evidence in hospitalized (but not necessarily critically ill or obese) patients that the negative N balance that normally accompanies calorie deficiency is prevented when low-calorie diets are supplemented with a sufficiently generous amount of protein. [32] [33] [34] This principle applies to all patients, not just to obese ones. It is well documented that most critically ill patients are "permissively underfed" (ie, globally calorie and protein deprived) for the first week or two of care in modern ICUs. 2 These patients are experiencing potentially preventable body protein loss for that reason alone. Several large RCTs recently indicated that supplementing permissive underfeeding with large amounts of calories does not improve clinical outcomes. 35, 36 What has not been tested, but plainly should be in light of this nutrition principle, is the hypothesis that early supplementation of standard-of-care calorie-and protein-deficient enteral nutrition (EN) with sufficiently generous amounts of protein will improve N balance and clinical outcomes in nonobese as well as obese patients. At present, the only clinical outcome RCT that has provided some evidence pertinent to this hypothesis was carried out in nonobese patients. 37 
Amino Acid Delivery
It has long been a keystone of nutrition guidelines to assert that parenteral nutrition (PN) is inherently more dangerous than EN and hence should be regarded as a treatment of last resort. The greatest concerns about PN are its ease of calorie overfeeding and apparently greater risk of infectious complications. EN has its own problem: it delivers too little protein, too late. 2 Investigators embarking on projects to identify optimum protein requirements in the ICU should be willing to design clinical trials in which standard (inadequate) EN is supplemented by hypocaloric amino acid-rich PN. The most recent ASPEN guidelines rate the quality of the evidence that PN is inferior to EN as low to very low. The differences in complication rates between EN and PN largely reflect findings from older studies when PN was commonly associated with overfeeding and hyperglycemia or the use of different fat emulsions. 11 A recent meta-analysis reported a slight advantage of EN over PN but concluded that the difference could be fully explained by the reduced calorie delivery associated with EN rather than the enteral route itself. 38 The advantage of hypocaloric parenteral amino acid supplementation is that it allows a suitably substantial, accurately known dose of amino acids to be provided safely and without delay. 30 
Clinical Outcomes
There are 3 kinds of outcomes: metabolic outcomes that provide physiological insight (such as metabolite, hormone or cytokine concentrations, or turnover), biomarker outcomes that can be used to make predictions about the plausibility of clinical benefit (such as N balance), and hard clinical outcomes. Biomarker outcomes are used in exploratory clinical trials to identify the appropriate target patient population and the optimum dose to use in future large, costly RCTs with hard clinical outcomes.
It is important to identify physiologically rational biomarkers and, when using them, to continually be reminded that they are provisional and potentially untrustworthy. For example, the most commonly used biomarkers in human protein nutrition are N excretion and N balance, where the hallmark of protein nutrition "success" is improved or neutral N balance. It is worth considering that exogenous protein may improve clinical outcomes by providing the substrate for protein synthesis in the central pool and at sites of injury without improving N balance. In the past, efforts were made to stimulate muscle protein anabolism in critically ill patients by infusing large doses of glucose and insulin. These treatments appear to have caused more harm than good, in part by driving amino acids into muscle and depriving central tissues and sites of injury of the amino acids they require for wound healing and immunoinflammatory regulation. 3 Continuing improvement in the quality and safety of ICU care has reduced acute ICU mortality but created a large population of medium-to long-term ICU survivors burdened with serious disabilities. 39, 40 Future clinical trials using the most promising level of protein provision should target both shortterm and longer-term clinical outcomes.
Three Recent Randomized Clinical Trials
A recent, small-enrollment but high-quality RCT compared the effects of standard hypocaloric, protein-deficient EN with hypocaloric high-protein EN. 37 N balance and muscle mass parameters were not determined. Although the trial lacked statistical power, and its high-protein arm delivered only 92 g protein/d, biomarker and other indicators nevertheless suggested better outcomes in the high-protein group. A second RCT compared standard-of-care global underfeeding by EN with the same EN supplemented by PN that provided intravenous mixed amino acids for a total daily protein dose of approximately 1.6 g/kg to critically ill patients with renal dysfunction. 41 (The published article overstates the amount of protein administered in the EN plus PN group by failing to adjust for the fact that the free amino acids in PN contain 17% less protein substrate than a similar mass of formed protein. 42 ) N balance and muscle mass parameters were not determined. The aim of the RCT was to determine whether increased amino acid provision could foster a better preservation of renal function; it did not. The primary end point of this RCT was a biological marker; as its authors point out, it was not powered to detect differences in patient-centered clinical outcomes. Another recent RCT enrolled critically ill patients who required PN to treatment groups that received either low (0.9 g/kg) or high (1.1 g/kg) daily amounts of mixed amino acids. 43 Muscle mass and handgrip strength, but not N balance, were measured. Despite the very modest protein dose in the high-protein arm and the minimal separation between the protein doses in the 2 study arms, certain indications of benefit were observed in the higher protein group. Taken together, these RCTs neither confirm nor refute the hypothesis that critical illness increases protein requirements. They do not attempt to identify a protein level specific to the intensity of the protein-catabolic response or stratify their outcomes according to the patients' existing muscle mass. They do, however, represent a marked improvement in clinical trial quality, and they demonstrate that the project of rigorously answering these questions is feasible.
Conclusions
The controlled environment of the ICU creates the opportunity to determine protein requirement values for critically ill patients in specific clinical situations. Clinical trials that aim to do this would benefit by incorporating the physiological principles used to define normal protein requirements. Increased muscle protein catabolism predicts an increased protein requirement. The clinically determinable metabolic signature of the protein-catabolic state is increased urinary N excretion. Therefore, urinary N should be estimated or surrogate clinical indicators of it identified and validated to identify patients whose protein requirement is likely to be increased. A patient's existing muscle mass sets an upper limit on the rate at which amino acids can be mobilized from their muscles to the benefit of central proteins and sites of tissue injury. It is therefore important to identify patients with existing muscle atrophy using evaluation methods that can easily be used at the bedside. Energy deficiency increases the dietary protein requirement. Yet in current ICU practice, patients are globally energy and protein deprived for the first week or two of an ICU stay. We now know that supplementing deficient EN with calories (but little protein) does not improve clinical outcomes. Clinical trials are urgently required to test the benefits of promptly supplementing deficient EN with suitably generous amounts of protein while strictly avoiding calorie overfeeding.
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Discussion
Ryan T. Hurt: Thank you for the nice talk; I would like to make two comments. Some of the points you made about the Doig and Heidegger studies I think are worth highlighting again. You stated that a mixture of free amino acids, each of which contains a molecule of hydration, necessarily provides 17% less protein than would be provided by the same weight of formed protein; this is important to appreciate when analyzing protein requirements in parenterally fed patients. The second comment is about the inadequacy of nutritional instruction in medical education you touched on. We have studied student opinions about clinical nutrition when they arrive to start medical school. At first they are generally very interested and excited about nutrition. This is despite their general lack of clinical knowledge about nutrition. By the time they're a fourth-year student, they've almost completely lost that interest in nutrition. So something happens during the 4 years where they've lost interest. One of the more important points in your talk (omitted from the published article) is that we have to somehow stimulate interest in nutrition and show them how it fits into clinical medicine and that it is not some the same as a biochemistry class.
L. John Hoffer:
We have the same experience at McGill University. An article published a decade ago documented that when medical students enter their first year, they have the same respect and interest in nutrition that the general public has, but it progressively decreases during their training.
1 It appears to me that medical students seek out role models as they create their identities as future doctors. By the time they get to a certain point in their education, the hidden curriculum of medicine, as it's called, has taught them that nutrition isn't what a "real doctor" cares much about. This is an unconscious bias, because they'll pay lip service to nutrition even as they remain incompetent in it. This is not necessarily easy to combat, and it's an important mission for us to think about strategies to overcome it. In my view, one of the greatest barriers to funding and carrying out the research necessary to determine protein requirements in disease states is the antinutrition bias that pervades modern academic medicine. Nutrition has never been more respected by the public, and doctors are in the public domain, but academic medicine trails behind.
The Heidegger article is terrific, but they didn't give enough protein or even devote much attention to it. The article text barely mentions "protein," instead concentrating on "full calorie support." They did give 1.2 g amino acids per kilogram of body weight, which is a lot more than most other trials, so some benefit might have been anticipated. A review in the ACP
